Pfizer Inc. (NYSE:PFE) Shares Sold by Amarillo National Bank

Amarillo National Bank trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 5.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 15,235 shares of the biopharmaceutical company’s stock after selling 943 shares during the period. Amarillo National Bank’s holdings in Pfizer were worth $404,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of PFE. Creative Planning grew its position in Pfizer by 17.1% in the 3rd quarter. Creative Planning now owns 1,820,731 shares of the biopharmaceutical company’s stock valued at $52,692,000 after buying an additional 266,167 shares in the last quarter. Swedbank AB grew its position in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. Bleakley Financial Group LLC grew its position in Pfizer by 2.7% in the 3rd quarter. Bleakley Financial Group LLC now owns 109,428 shares of the biopharmaceutical company’s stock valued at $3,167,000 after buying an additional 2,914 shares in the last quarter. Aaron Wealth Advisors LLC grew its position in Pfizer by 41.7% in the 3rd quarter. Aaron Wealth Advisors LLC now owns 16,576 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 4,878 shares in the last quarter. Finally, Richard W. Paul & Associates LLC grew its position in Pfizer by 1.6% in the 3rd quarter. Richard W. Paul & Associates LLC now owns 31,692 shares of the biopharmaceutical company’s stock valued at $917,000 after buying an additional 494 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent analyst reports. Bank of America reiterated a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Wolfe Research started coverage on shares of Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 price objective for the company. Guggenheim restated a “buy” rating and set a $33.00 price objective on shares of Pfizer in a research report on Monday, February 10th. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research report on Wednesday, October 23rd. Finally, Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Price Performance

NYSE PFE opened at $25.50 on Friday. The company has a 50 day simple moving average of $26.28 and a 200-day simple moving average of $27.58. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $144.48 billion, a price-to-earnings ratio of 18.08, a price-to-earnings-growth ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analyst estimates of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue was up 24.7% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.10 earnings per share. Equities research analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.75%. The ex-dividend date is Friday, January 24th. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Insider Activity at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business’s stock in a transaction that occurred on Thursday, February 13th. The shares were purchased at an average price of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.